ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

RayzeBio garners $45 million in series A funding for radiopharmaceuticals

by Megha Satyanarayana
October 17, 2020 | APPEARED IN VOLUME 98, ISSUE 40

 

RayzeBio is launching with $45 million in series A funding to develop radioisotope therapies for cancer. The company makes radiopharmaceuticals using macrocyclic peptides and actinium-225 that can be used for both diagnostic imaging and treatment by switching out the isotope. The company says a clinician can see a tumor’s uptake of a possible treatment before proceeding with it. RayzeBio has a partnership with PeptiDream to develop the peptides.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment